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Abstract
Each year, evidence-based clinical guidelines gain more space in the health professionals’
practice and in services organization. Due to the scarcity of scientific publications focused
on diseases of poverty, the development of well-founded clinical guidelines becomes more
and more important. In view of that, this paper aims to evaluate the quality of Brazilian guide-
lines for those diseases. The AGREE II method was used to evaluate 16 guidelines for pov-
erty-related diseases (PRD) and 16 guidelines for global diseases whose treatment require
high-cost technologies (HCD), with the ultimate aim of comparing the results. It was found
that, in general, the guideline development quality standard is higher for the HCD guidelines
than for the PRD guidelines, with emphasis on the "rigour of development" (48% and 7%)
and "editorial independence" (43% and 1%) domains, respectively, which had the greatest
discrepancies. The HCD guidelines showed results close to or above international aver-
ages, whereas the PRD guidelines showed lower results in the 6 domains evaluated. It can
be concluded that clinical protocol development priorities need some redirecting in order to
qualify the guidelines that define the healthcare organization and the care of vulnerable
populations.
Introduction
The advancement of evidence-based health care has positively impacted patient care, improv-
ing diagnostic accuracy, guiding healthcare professionals on using the most effective therapy,
and reducing patient exposure to ineffective or even harmful interventions [1].
In view of the great advance of scientific studies in the health area, one can state that access
to the best available evidence is a right of the health professional and the patient, target of the
health intervention. Well-developed clinical guidelines have the power to mediate different
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interests in health care policy, best practice, government funding, local contexts, and patient
choice [2].
Yet, the great number of clinical guidelines continuously produced without an acceptable
quality standard that supports their recommendations leads to discrediting of such a funda-
mental mechanism of health care qualification. Several guidelines developed for the care of the
same disease and produced with different methods and objectives can generate unnecessary
competition and a complex system of conflicting practices and interventions [3].
In Brazil, since 2000 there has been a movement for clinical guideline qualification using
structured methods for the development and publication of the so-called “Clinical Protocols
and Therapeutic Guidelines (PCDTs)”. Early versions of those documents include a small
number of clinical conditions for which the cost of treatment, especially medicines, was con-
siderably high.
After the enactment of Law No. 12,401 and Decree No. 7,508, both in 2011 (on therapeutic
care and technology incorporation in the Brazilian health system), the PCDTs began to gain
institutional legitimacy and greater coverage, becoming a reference document for disease or
condition diagnosis, pharmacological and non-pharmacological treatment, patient follow-up
and verification of therapeutic results [4]. Thus, in the context of the Brazilian Unified Health
System (SUS, the national public health system), the PCDTs are referred to as Clinical Practice
Guidelines, sometimes shortened as Clinical Guidelines.
The PDCTs are applied, also, on regulating and controlling the free access to high-cost
treatment. High-cost medicines is an expression without a uniform definition but adopted by
the Pan American Health Organization and partner countries to define therapies that are the
major burden for the financing of the health system and / or high household expenditure. It is
characterized generally by a greater interest of the pharmaceutical industry and consequently
more number of launches / innovations and patents. These medicines are particularly applied
for the so called “global diseases”, those that did not have the socioeconomic vulnerability bias
as a fundamental determinant [5,6,7,8]. In Brazil, those diseases are covered by a program
called Specialized Component of Pharmaceutical Assistance [4].
On the other hand, according to the conceptual propositions of the Me´decins Sans Fron-
tières (MSF, or Doctors Without Borders) and the World Health Organization (WHO), tropi-
cal, neglected or related to poverty diseases have opposite characteristics, with less interest of
the pharmaceutical industry and consequently smaller number of medicines available, innova-
tions and patents. They are often characterized by requesting older and less expensive drugs
for the health system. In Brazil, these drugs are mostly produced by public laboratories and
covered by the public program called Strategic Conditions Component of the Pharmaceutical
Assistance [5, 6]. In this country, poverty-related diseases are particularly important health
issues. They are the result of poor living conditions, insufficient access to adequate and healthy
food, clean drinking water, medical care and education [5,6,7,8]. Some infectious diseases such
HIV, considered related to poverty globally, in Brazil is not classified as neglected or poverty
related. Particular healthcare facilities and guidelines are available and accessible.
Most of the so-called poverty-related and neglected diseases and conditions, however, are
still addressed by the SUS in the form of different documents such as guides, manuals and
handbooks formulated in diverse methodological ways rather than in a standardized way in
line with the PCDTs’ structures.
In this sense, this paper aims to evaluate the methodological quality of the documents pub-
lished by the Brazilian Ministry of Health addressing care guidelines for the population
affected by poverty-related diseases, in an attempt to verify their compliance with evidence-
based health standards and consequently the needs of health caregivers and patients.
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Methods
Identification and selection of clinical guidelines
The study included only clinical guidelines published by the Brazilian Ministry of Health for
the diseases or conditions covered by the Specialized Component of Pharmaceutical Assistance
and the Strategic Conditions Component of the Pharmaceutical Assistance. Documents issued
by states, municipalities or other health institutions were not included in the analysis. Like-
wise, posters, flyers or like documents that did not fit the structure of care guides or protocols
were not considered, even if they contained therapeutic conduct guidelines.
Given the variety of documents for the same disease or condition, the quality assessment
included the most recently published ones and with the most detailed information on care
(clinical condition, diagnostic and therapeutic conduct and the target population of the pro-
posed interventions). At that moment (2016), sixteen documents had been published by the
Ministry of Health about diseases or conditions classified as poverty-related, presenting treat-
ment guidelines and covered by the Strategic Conditions Component of Pharmaceutical Assis-
tance. As a comparison criterion with the global disease guidelines, the study sample included
all the PCDTs issued by the CONITEC (National Committee for Health Technology Incorpo-
ration in the SUS) and published as Ministry of Health Ordinances in 2015, the immediate
year before the study. Sixteen PCSTs were published in that year. The main characteristic of
these PCDTs is their focus on the so-called ’high-cost diseases’, included in the Specialized
Component of Pharmaceutical Assistance (CEAF). The 32 guidelines selected for the study are
described in Table 1:
Methodological quality assessment: The AGREE II instrument
The quality analysis of the selected clinical guidelines was performed using the AGREE–
Appraisal of Guidelines for Research and Evaluation, an assessment instrument developed
from analyses of over 100 guidelines selected and evaluated independently by more than 200
evaluators from different parts of the world. It is used by the WHO and various technology
assessment agencies worldwide as a reference tool for quality assessment of clinical practice
guidelines. Its last edition (AGREE II) has 23 key items organized within six quality domains
[9,10].
Following the AGREE II instructions, the guidelines selected for this study were appraised
by four independent experts with previous experience in clinical practice guideline assessment
[11]. As commonly observed, similar studies have been using two or three appraisers; however
the instrument recommends ideally four appraisers [9,11–13].
Data extraction, management and analysis
Data were collected from the six quality domains described in the AGREE II Instrument: (i)
scope and purpose; (ii) stakeholder involvement; (iii) rigour of development; (iv) clarity of pre-
sentation; (v) applicability, and (vi) editorial independence. The instrument provides a score
sheet with ratings from 1 (strongly disagree) to 7 (strongly agree) for each of the 23 items. At
the end, a quality score is calculated for each of the six AGREE II domains [11]. A percentage
of suitability of each domain with values from 0% to 100% was also calculated using the score
obtained by each evaluator and possible maximum score of the domain, following the guide-
lines of the AGREE II Instrument.
Although not suggested by the instrument, this study performed a concordance analysis
among the appraisers, using the kappa test in order to avoid randomness or poor agreement.
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Kappa coefficients of moderate agreement (kappa> 0.4) were considered preferable for this
type of study [12, 14].
For the concordance analysis, the appraisers decided jointly that scores 1 and 2 would be
considered "low", scores between 3 and 5 would be "intermediate", and scores 6 and 7 "high".
By evaluating the agreement between these categories, an initial kappa of 0.263 was obtained.
Subsequently, a meeting was held with the appraisers to discuss the main dissenting opinions
on the assessment criteria. The major divergences were remedied by re-reading and discussing
together (all the appraisers) guidelines of the AGREE II Instrument [11]. After a new indepen-
dent assessment, a final kappa of 0.598 was obtained, corresponding to a moderate agreement.
Table 1. Clinical guidelines of the Brazilian Ministry of Health selected for the study.
Acronym Selected guideline (translated from the Portuguese title)
PRD 01 Health Surveillance Guide (2014)
PRD 02 Guide to Infectious and Parasitic Diseases (2010)
PRD 03 Reference Guide to Epidemiologic Surveillance, Nutrition Assistance in Beriberi Cases (2012)
PRD 04 NutriSUS: evidence guidelines: food fortification strategies for infant nutrition with micronutrient
(vitamins and minerals) powders (2015)
PRD 05 General Guidelines of the National Vitamin A Supplementation Program (2013)
PRD 06 National Iron Supplementation Program: General Guidelines (2013)
PRD 07 Dengue: Diagnosis and Clinical Management - Adults and Children (2016)
PRD 08 Sickle Cell Disease: Basic Guidelines for the Treatment (2012)
PRD 09 Schistosomiasis Mansoni Surveillance: Technical Guidelines (2014)
PRD 10 Protocol on Health Care and Response to the Occurrence of Microcephaly Related to Zika Virus
Infection (2016)
PRD 11 Guide to Epidemiologic Surveillance and Elimination of Lymphatic Filariasis (2009)
PRD 12 Technical Operations Manual - Guidelines for surveillance, care and elimination of leprosy as a public
health problem (2016)
PRD 13 Leptospirosis: Diagnosis and Clinical Management (2014)
PRD 14 PCDTs for Comprehensive Care for People with Sexually Transmitted Infections (2016)
PRD 15 Guide to Surveillance and Elimination of Trachoma as a Cause of Blindness (2014)
PRD 16 Prevention and treatment of injuries caused by sexual violence against women and girls (2012)
HCD 17 PCDT Rheumatoid Arthritis (2015)
HCD 18 PCDT Chronic Hepatitis C Virus Infection and Co-Infections (2015)
HCD 19 PCDT Breast Cancer (2015)
HCD 20 PCDT Reactive Arthritis (2015)
HCD 21 PCDT Head and Neck Cancer (2015)
HCD 22 PCDT Celiac Disease (2015)
HCD 23 PCDT Amyotrophic Lateral Sclerosis (2015)
HCD 24 PCDT Multiple Sclerosis (2015)
HCD 25 PCDT Hyperprolactinemia (2015)
HCD 26 PCDT Congenital Hypothyroidism (2015)
HCD 27 PCDT Hereditary Ictioses (2015)
HCD 28 PCDT Primary Adrenal Insufficiency (2015)
HCD 29 PCDT Myasthenia Gravis (2015)
HCD 30 PCDT Multiple Myeloma (2015)
HCD 31 PCDT Guillain-Barre´ Syndrome (2015)
HCD 32 PCDT Non-infectious Uveitis (2015)
PRD = Poverty-Related Diseases; HCD = High-Cost Diseases
() Last update
https://doi.org/10.1371/journal.pone.0204723.t001
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The non-parametric Mann-Whitney test was applied to compare the mean score difference
of the guidelines in the six domains. The results were compared using program Statistical
Package for the Social Sciences—SPSS (IBM, v. 20) with the level of significance set at 5%.
The instrument does not define a standard that indicates whether or not the guideline as a
whole should be recommended. So, in order to make the assessment less subjective in that
respect, it was agreed in this study that the domain (iii) “rigor of development” would be the
main standard for the overall assessment of the guideline. Based on criteria suggested by other
authors [9,10,12] the evaluators defined 50% as the minimum score for “rigor of develop-
ment”, although some authors suggest a higher one. For a guideline to be considered as "rec-
ommended" it had to score higher than 50% in "rigor of development" and in two other
domains; the guideline that scored between 30% and 50% in "rigor of development" and higher
than 50% in two other domains was considered "recommended, with modifications"; and,
lastly, the guideline that scored less than 30% in "rigor of development" was considered "not
recommended".
Results and discussion
The various types of guideline documents evince the dissent among their denominations: "pri-
mary care handbooks", "guides", "protocols", "general guidelines", "manuals", "technical guide-
lines", among other terms adopted by the Brazilian Ministry of Health. Indeed, there are some
conceptual differences between those terms, but there also seems to be no consensus in the
Brazilian literature about the standard designation of this type of document, which we have
chosen here to call generically as a “clinical guideline”. However, the lack of standardized pub-
lications by the federal health agency may hinder the access to this information, both for
researchers and target health professionals [9,10,12].
The diversity of healthcare recommendations for the same disease seems harmful insofar as
they can generate conflicts concerning the suggested clinical conduct given the different guide-
line production methods used and the different results presented in the publications in
question.
The AGREE II instrument, however, is sensitive to different types of guidelines as it assesses
comprehensive and necessary issues for any type of therapeutic care guideline. The assessment
results are expressed as quality scores (0 to 100) for each domain and each of the 32 guidelines
validated in this study (Table 2).
Table 3 displays the assessment results in a direct comparison between the two guideline
groups evaluated (PRD x HCD), based on the ratings (1 to 7) obtained in each domain. There
was a statistically significant difference between the mean scores contrasted.
Domain 1—Scope and purpose
Fundamentally, this domain aims to analyze whether the guideline objectives, the diseases cov-
ered and the target population are well defined. The high-cost diseases guidelines showed
higher scores (86% or 6.2) when compared to those of poverty-related diseases (74% or 5.4),
although the latter still presented high scores.
It should be noted that the standard format of the HCDs accurately define the conditions
covered by the guideline, using the codes of the International Statistical Classification of Dis-
eases and Related Health Problems (ICD-10) and clearly describing the "inclusion" and "exclu-
sion" criteria. Molino et al. (2016) and Ronsoni et al. (2015) also found higher scores in this
domain, although their studies were restricted to assessments of clinical protocols for non-
communicable diseases [9,12].
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Domain 2—Stakeholder involvement
It evaluates the composition and degree of expertise of the group involved in drafting the
guideline. In this domain, the ratings and quality scores dropped in both guideline groups;
Table 2. Quality scores of the guidelines assessed as per the AGREE II instruction.
Guideline Scope and purpose Stakeholder involvement Rigour of development Clarity of presentation Applicability Editorial independence
PRD 01 65% 10% 5% 51% 24% 4%
PRD 02 46% 24% 1% 43% 10% 4%
PRD 03 68% 26% 8% 54% 40% 4%
PRD 04 57% 24% 11% 51% 25% 2%
PRD 05 86% 31% 7% 53% 43% 0%
PRD 06 74% 18% 5% 60% 39% 0%
PRD 07 82% 7% 4% 58% 22% 0%
PRD 08 75% 7% 6% 65% 20% 0%
PRD 09 81% 40% 8% 71% 44% 0%
PRD 10 88% 35% 4% 65% 35% 0%
PRD 11 63% 26% 6% 54% 31% 0%
PRD 12 74% 31% 6% 67% 33% 0%
PRD 13 76% 35% 3% 75% 32% 0%
PRD 14 88% 58% 19% 79% 45% 0%
PRD 15 79% 21% 4% 57% 35% 0%
PRD 16 78% 24% 8% 68% 42% 0%
HCD 17 94% 40% 57% 93% 30% 46%
HCD 18 97% 40% 53% 90% 25% 40%
HCD 19 89% 39% 53% 75% 33% 27%
HCD 20 83% 42% 52% 65% 22% 46%
HCD 21 81% 43% 43% 61% 33% 27%
HCD 22 86% 44% 47% 58% 26% 46%
HCD 23 86% 44% 46% 75% 23% 46%
HCD 24 88% 44% 45% 76% 26% 46%
HCD 25 85% 44% 49% 74% 22% 46%
HCD 26 85% 44% 44% 63% 19% 46%
HCD 27 85% 44% 49% 63% 24% 46%
HCD 28 83% 42% 46% 64% 23% 46%
HCD 29 85% 44% 46% 72% 27% 46%
HCD 30 85% 44% 42% 61% 30% 46%
HCD 31 85% 44% 45% 61% 21% 46%
HCD 32 83% 43% 45% 69% 22% 46%
https://doi.org/10.1371/journal.pone.0204723.t002
Table 3. Mean score of each domain comparing the guideline groups of poverty-related diseases and high-cost
diseases as per the AGREE II.
Quality domain PRD HCD P Value
Scope and purpose 5.4 ±0,69 6.2 ±0,25 < 0.01
Stakeholder involvement 2.6 ±0,78 3.6 ±0,11 < 0.01
Rigour of development 1.4 ±0,25 3.9 ±0,25 < 0.01
Clarity of presentation 4.6 ±0,59 5.2 ±0,62 < 0.01
Applicability 2.9 ±0,59 2.5 ±0,27 < 0.05
Editorial independence 1.1 ±0,10 3.6 ±0,39 < 0.01
https://doi.org/10.1371/journal.pone.0204723.t003
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however the HCD mean scores (43% or 3.6) kept higher than those of PRD (26% or 2.6). The
analysis revealed two weaknesses, namely the lack of commitment of all professional groups
involved and the failure to promote participation of the target population. For instance, the
sickle cell guideline (PRD 08), which had the lowest quality score in the domain (7%), was
drawn up by only two medical specialists, with no reported participation of other health pro-
fessionals or methodologists committed to evidence search and analysis.
An important difference between the assessed groups is that all the HCD guidelines were
previously approved by the CONITEC and made available for public consultation and social
collaboration in general. Only one guideline (PRD 14) of the PRD group was previously
reviewed by the CONITEC and underwent a public consultation. None of the 32 guidelines
evaluated in this study reported any kind of active patient participation in their development.
Effective patient participation in clinical guidelines development has been shown as a global
difficulty due to issues concerning the closed structure of the Health Technology Assessment
(HTA) area and patients’ suspicion that the guideline developers might be influenced by phar-
maceutical companies [15,16]. However, various studies have demonstrated that this strategy
is crucial to improve the quality of the recommendations, since it allows identifying discordant
points between professionals and patients, identifying priority needs from the perspective of
users; points that are not well observed by guideline developers and managers which can help
improve the strategies for guideline adherence and implementation [17,18].
Domain 3—Rigor of development
This domain showed one of the greatest disparities among the groups evaluated, where the
quality score of the HCD guidelines, i.e. the compliance level with the criteria of the instru-
ment, was almost seven times greater (48%) than that of the PRD guidelines (7%), and their
mean score (3.9) was almost three times higher (1.4), respectively.
It was found that some key questions for guideline quality assessment were totally neglected
in the PRD guidelines analyzed, for instance, description of the search methods, evidence
selection criteria, strengths and limitations of the evidence, formulation of recommendations,
consideration of benefits and harms, in addition to external review methodology and proce-
dure for updating the guideline.
Among the guidelines evaluated, the Guide to Infectious and Parasitic Diseases (PRD 02) had
the lowest quality score (1%). It is a publication intended to be a quick guide to basic care. However,
it does not have a section informing the reader about the methods used to formulate the recom-
mendations and it does not even provide bibliographic references. Notwithstanding, the Guide has
the highest circulation among the publications evaluated, with 90 thousand printed copies.
Molino et al. (2016) and Ronsoni et al. (2013) reviewed some HCD guidelines of the Brazil-
ian Ministry of Health and found similar quality scores in this domain, with mean values of
41% and 36%, respectively [12, 19].
Decrees No. 7508/11 and No. 7646/11 establish that the PCDTs of the Brazilian Ministry of
Health must be updated every two years, conferring to the CONITEC the constitution or mod-
ification of such guidelines. All of the HCD documents reviewed in this study met these stan-
dards. Of the 16 PRD guidelines evaluated, two (PRD 02 and PRD 09) were published before
those decrees and, among the others, only one (PRD 14) was published in accordance with the
aforementioned decrees [4, 20, 21].
Domain 4—Clarity of presentation
This is the second domain with the highest scores, even with the trend of higher mean scores
of the HCD guidelines (70% and 5.2) when compared to those of the PRD guidelines (61% and
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4.6). In general, the guidelines in both groups were written in plain language, often addressing
various aspects of the health issue.
The HCD guidelines are more concise than the PRD ones. The latter have a wide variety of
formats and sizes of documents, contrasting with the first group, which had a standard format
previously established by a specific ordinance that offered a roadmap for the PCDTs develop-
ment, and consequently showed a more coherent presentation [22, 23].
Domain 5—Applicability
The “applicability” domain scored low in both groups. This domain includes questions that
describe facilitators and barriers to the guidelines’ application, potential resource implications
and monitoring criteria [11].
Despite the small margin of difference, the PRD guidelines scores were higher (33% and
2.9%) than those of the HCD guidelines (25% and 2.5%). This demonstrates a certain concern
of guideline development panels with the application of the guidelines in contexts of greater
operational difficulty. The normative character and little approach to guideline implementa-
tion actions were previously described by other authors who evaluated some PCDTs of the
Brazilian Ministry of Health, finding results similar to those of the present study, such as those
by Ronsoni et al. (2015), Ronsoni (2013) (37.5% and 3.3) and Molino et al. (2016) (34%) [9, 12,
19].
Domain 6—Editorial independence
Similar to the "rigour of development" domain, this was one of the domains that showed the
highest discrepancy between the scores of the HCD guidelines (43% and 3.6) and the PRD
guidelines (1% and 1.1). This item evaluates the degree of reliability and equity in the guideline
development. In this item, it is expected that there will be information and statements that
demonstrate that the views or interests of the funding body did not influence the final
recommendations.
The HCD guidelines did not reach higher scores solely because they did not specify more
clearly the procedures used to avoid the funding bodies’ influence on their content and how
potential competing interests were managed. However, there were supplementary documents
and terms defining the procedures and responsibilities of each group of participants, and spec-
ifying that a declaration of competing interests was signed by all parties [12, 23].
On the other hand, the PRD guidelines did not have any similar procedure or standard, and
there was no record attesting that a competing interest statement was signed or any actions
were taken to avoid the funding bodies’ influence on the content and formulation of
recommendations.
This points to a variability in the areas of the Ministry of Health concerning the procedures
for declaring competing interests and how these conflicts are handled (or not). These are
essential steps to ensure that the content of the recommendations is unbiased and the publica-
tions are reliable [2,3].
International comparison
With the intention of analyzing the results from an international standpoint, the quality scores
per domain were compared with the findings of Alonso-Coello et al. (2010), who carried out a
systematic review of studies from around the world that brought together 625 different guide-
lines. Fig 1 was prepared with the most current data from that study, including guidelines pub-
lished since 2003 [13].
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It can be seen that, in general, the HCD guidelines are in line with international standards,
with similar and slightly higher scores in all the domains evaluated.
The PRD guidelines, on the other hand, showed lower scores in most domains. The main
contrasts can be noticed in the "rigor of development" and "editorial independence" domains,
reinforcing the findings that these documents have methodological criteria problems in what
concerns evidence-based health and the procedures adopted to guarantee an unbiased process.
Overall guideline assessment
The comparison of this study’s results with international findings demonstrates the effective-
ness of the method used. However, the participating appraisers did not consider it appropriate
to individually assess whether a particular guideline would be recommended or not for use, as
described in the AGREE II. Therefore, the appraisers decided to adopt criteria based on the
analysis of previous domains.
Due to the greater emphasis on the "rigor of development" domain in similar studies
[12,13,24,25], it was decided that this domain should be the central item for guideline assess-
ment because of its relevance and greater number of analysis parameters.
According to the abovementioned criteria, the PCDTs for Rheumatoid Arthritis (HCD 17),
Hepatitis C Virus Infection (HCD 18) and Breast Cancer (HCD 19) were considered as "rec-
ommended", and the other HCD guidelines (20 to 32) were considered as "recommended,
with modifications". This result is in line with three other similar studies which pointed out
that the PCDTs of the Ministry of Health, even with a methodological standard comparable to
other international guidelines and superior to other Brazilian guidelines, need continuous
improvement [9,12,19].
All the PRD guidelines (01 to 16) were considered as "not recommended" since, according
to the AGREE II assessment, they did not meet the minimum criteria of the scientific method
description, failing to provide whether or not the document was drawn up from an evidence-
based health perspective.
The clinical guidelines with the highest score percentage in the AGREE II concern diseases
that demand a heavy medicine expenditure of the Ministry of Health, namely, rheumatoid
arthritis, hepatitis C virus infection and breast cancer, precisely those with a billion dollar bud-
getary impact for the Brazilian health system and for most health systems in developed
Fig 1. Quality scores of the AGREE II domains compared to the international guidelines in Alonso-Coello et al.
(2010).
https://doi.org/10.1371/journal.pone.0204723.g001
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countries [26, 27]. The lowest scores were of documents addressing the treatment of poverty-
related diseases of low visibility such as intestinal parasitosis, human brucellosis, onchocercia-
sis, trachoma, among others. This indicates that the safety of patients suffering from such dis-
eases and undergoing treatment cannot be ensured by the current treatment protocols.
This contrasts with the influence that budget pressure exerts on action priorities and invest-
ments in health qualification. This does not seem to be a coherent decision, since it is poverty-
related diseases that have less potential for evidence generation due to less investment in clini-
cal research and new technology development. Despite the decline in the number of cases of
these diseases over the years, given the ongoing epidemiological transition, they still have a
major impact on morbidity and mortality when we look at disease burden data, in addition to
the contemporary risk of re-emergence of some previously controlled epidemics [6]. In addi-
tion, there is a trend for such issues to be less addressed in health training curricula, which
consequently generates a greater need for consistent clinical guidelines [28].
Final remarks
Based on the findings of this study, it is possible to verify a double quality standard in clinical
guideline development of the Brazilian Ministry of Health, where the guidelines for global dis-
eases that demand high-cost technologies showed higher scores in the AGREE II assessment
when compared to those for poverty-related diseases which, normally, demand old and low-
cost technologies.
Discrepancies found in quality and methods of selection, use of scientific evidence, and edi-
torial transparency criteria are of concern and should be reviewed for the poverty diseases
guidelines. Future studies must include the clinical credibility and implementation of guideline
recommendations, as recommended by the new AGREE-REX [29]. This study did not include
some of the most ordinary diseases, as those most frequent in primary health care services
(such as diabetes and hypertension) and can add a broader view of guidelines development in
Brazilian health system.
It can be inferred that the budgetary power and resource pressure also influence the action
priorities and the quality of care in the public sector, making diseases that are neglected by the
pharmaceutical market also be neglected at certain levels by the health system.
The neglect of the poverty-related diseases observed in this study concerns not only finan-
cial, scientific and product development investments but also the standardization and quality
of the clinical services offered to the affected population.
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